4-N-aminoacylfortimicins E.

Kurath, Paul; Grampovnik, Dave; Tadanier, Jack; Martin, Jerry R.; Egan, Richard S.; Stanaszek, Ruth S.; Cirovic, Momir; Washburn, William H.; Hill, Preston J.; Dunnigan, Daniel A.; Leonard, J.E.; Johnson, Paulette; Goldstein, Alma W.

doi:10.7164/antibiotics.32.884

Cited by 11 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these new compounds, the fortimicin group has been most extensively tested against recent clinical isolates (7). Numerous chemical and natural modifications of fortimicin have been presented (6,8,10,14,15). Fortimicin aminoglycosides are generally resistant to inactivating enzymes (6, 10, 13), but lack significant inhibitory activity against pseudomonads (6, 7).…”

mentioning

confidence: 99%

Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics

Jones¹,

Thornsberry²,

Barry³

et al. 1980

Antimicrob Agents Chemother

View full text Add to dashboard Cite

O-Demethylfortimicin A (compound A49759) was tested against 445 bacteria, and the results were compared with thooe obtained with fortimicin A, amikacin, gentamicin, netilmicin, sisomicin, and tobramycin. A49759 was found to be active and bactericidal against the Enterobacteriaceae, nonfermentative gram-negative bacilli, and Staphylococcus aureus. A49759 was two-to fourfold more active than fortimicin A against most species tested, but generally fourfold less active than amikacin against this population of Pseudomonas aeruginosa (85% inhibited at -16 ug of amikacin per ml and 85% inhibited at c64 ,ug of A49759 per ml). Only amikacin and A49759 were resistant to most aminoglycoside-inactivating enzymes and also had significant antipseudomonal activity. Amikacin was inactivated by aminoglycoside 6'-acetyltransferase, and A49759 was inactivated by aminoglycoside 3-acetyltransferase. The minimal inhibitory concentrations of all tested aminoglycosides were increased by augmenting the inoculum size. Several recent reports have described the in vitro antimicrobial activity of the pseudodisaccharide aminoglycoside antibiotics (4-8, 10, 11, 13, 14). Among these new compounds, the fortimicin group has been most extensively tested against recent clinical isolates (7). Numerous chemical and natural modifications of fortimicin have been presented (6,8,10,14,15). Fortimicin aminoglycosides are generally resistant to inactivating enzymes (6, 10, 13), but lack significant inhibitory activity against pseudomonads (6, 7). In recently presented abstracts no ototoxicity and very low renal toxicity for fortimicin A in the animal models were described (C. L

show abstract

mentioning

confidence: 99%

Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics

Jones¹,

Thornsberry²,

Barry³

et al. 1980

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…olivoasterospora. − To the best of our knowledge, 23 natural fortimicins (FTMs) or FTM epimers ( 54 – 76 ) have been isolated and identified as of 2021 (Figure ). ,− FTM A ( 54 ) from the soil-derived strain ATCC 2189 had a bactericidal effect on Escherichia coli and Staphylococcus epidermidis by inhibiting protein synthesis in vivo . It also showed excellent activity against Enterobacteriaceae strains compared to those of amikacin, gentamicin, sagamicin, and tobramycin .…”

Section: Bioactive Secondary Metabolites Of Micromonosporamentioning

confidence: 99%

Micromonospora: A Prolific Source of Bioactive Secondary Metabolites with Therapeutic Potential

et al. 2022

View full text Add to dashboard Cite

Micromonospora, one of the most important actinomycetes genera, is well-known as the treasure trove of bioactive secondary metabolites (SMs). Herein, together with an in-depth genomic analysis of the reported Micromonospora strains, all SMs from this genus are comprehensively summarized, containing structural features, bioactive properties, and mode of actions as well as their biosynthetic and chemical synthesis pathways. The perspective enables a detailed view of Micromonospora-derived SMs, which will enrich the chemical diversity of natural products and inspire new drug discovery in the pharmaceutical industry.

show abstract

F

Collins¹

1998

Dictionary of Carbohydrates

View full text Add to dashboard Cite

4-N-aminoacylfortimicins E.

Cited by 11 publications

References 10 publications

Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics

Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics

Micromonospora: A Prolific Source of Bioactive Secondary Metabolites with Therapeutic Potential

F

Contact Info

Product

Resources

About